DANIELLE GIPSON: Open Payments
NPI 1518447911 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,524 in 132 payments from 11 companies in 2025. Trend: 2023 $1,150 · 2024 $963 · 2025 $2,524
Food & beverage: $2,412Education: $111
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 34 | $544 |
| Neurocrine BioSciences, Inc. | 16 | $425 |
| Otsuka America Pharmaceutical, Inc. | 16 | $283 |
| Teva Pharmaceuticals USA, Inc. | 15 | $278 |
| Janssen Pharmaceuticals, Inc | 11 | $239 |
| Axsome Therapeutics, Inc. | 6 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $190 |
| Alkermes, Inc. | 9 | $156 |
| Vanda Pharmaceuticals Inc. | 4 | $85 |
| ABBVIE INC. | 4 | $71 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, Auvelity, CAPLYTA, ABILIFY MAINTENA, ARISTADA, REXULTI.
Industry payments across TX — which companies pay providers there.
